CARE-HF extension demonstrates a sustained benefit of CRT
This article has no abstract so we have provided the first paragraph of the full text.
The Cardiac Resynchronization in Heart Failure (CARE-HF) trial investigated the benefits of cardiac resynchronization therapy (CRT) in patients with persistent moderate or severe symptoms of heart failure. This open-label randomized trial assigned patients to either medical therapy alone (n = 404) or medical therapy with implantation of a CRT device (n = 409). After a mean follow-up of 29.4 months, CRT produced benefits over medical therapy alone in terms of reductions in morbidity and mortality, as well as improving cardiac function, symptoms and quality of life.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
L-DOPA, dyskinesia and striatal plasticityNature Neuroscience News and Views (01 May 2003)
